Survival benefit of tofacitinib in interstitial lung disease associated with anti-MDA5-positive dermatomyositis: a need for further validation

Chih-Wei TsengJames Cheng-Chung Wei2026-02-052026-02-052025-0710.1183/13993003.00306-2025https://scholars.csmu.edu.tw/handle/123456789/5293[SDGs]SDG3Survival benefit of tofacitinib in interstitial lung disease associated with anti-MDA5-positive dermatomyositis: a need for further validationjournal-article